AbCellera's ABCL635 Phase 2 Trial for Hot Flashes Achieves Best-in-Class Efficacy and Favorable Safety
ABCL has more than doubled off its 52-week low of $2.745.
Summary
AbCellera reported strong Phase 2 results for ABCL635, its hot flash treatment, showing best-in-class efficacy and a good safety profile, paving the way for further development.
Updates
· Benzinga — Detailed Phase 2 data: 600 mg dose reduced daily hot flashes by 8.8 vs 3.5 for placebo (p<0.001), an 83% reduction from baseline; severity scores dropped 1.4 vs 0.3 (p<0.001). No serious adverse events or discontinuations. Shares rose 33%.
Key Events · Product Development and Regulatory · ABCL
-
ABCL635 Phase 2 Trial Success
The investigational antibody ABCL635 met primary efficacy endpoints in its Phase 2 trial for moderate-to-severe vasomotor symptoms (hot flashes).
-
Best-in-Class Efficacy
Results showed statistically significant and "best-in-class" reductions in both the frequency and severity of hot flashes, along with improved sleep.
-
Favorable Safety Profile
ABCL635 demonstrated a favorable tolerability profile with no serious adverse events, supporting its potential as a long-acting, non-hormonal treatment.
-
Advancement to Late-Stage Development
The positive data supports advancing ABCL635 to late-stage clinical development, targeting a significant market for menopausal and cancer treatment-induced VMS.
Analysis · ABCL · Life Sciences
AbCellera Biologics announced highly positive top-line Phase 2 results for ABCL635, its investigational antibody for moderate-to-severe vasomotor symptoms (hot flashes). The trial met all primary efficacy endpoints, demonstrating statistically significant and "best-in-class" reductions in both frequency and severity of symptoms, alongside improved sleep and a favorable safety profile. This successful Phase 2 readout significantly de-risks the program and supports advancement to late-stage development, targeting a large unmet medical need. The stock is trading near its 52-week high, and this positive clinical data could provide further upward momentum.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 43.6% of the 289 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABCL was trading at $8.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $2.75 to $8.44. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.